Pharmaceutical and pharmacokinetic evaluation of a newly formulated multiparticulate matrix of levodopa and carbidopa
Open Access
- 15 October 2022
- journal article
- research article
- Published by International Association of Physical Chemists (IAPC) in ADMET and DMPK
- Vol. 11 (1) , 97-115
Abstract
Levodopa is routinely co-administered with carbidopa in the management of Parkinson’s disease. Although the aforementioned combination therapy is effective, there may be fluctuating plasma levels of levodopa after oral administration. We formulated and evaluated the kinetic characteristics of the chitosan-pectin-based multiparticulate matrix of levodopa and carbidopa. Pectin was extracted from the cocoa husk, and the chitosan-pectin-based matrix was prepared by wet granulation. Formulations were evaluated for drug-excipient compatibility, drug content, precompression properties and in vitro release. For pharmacokinetic evaluation, rats were put into groups and administered either chitosan-pectin based matrix of levodopa/carbidopa, Sinemet® CR or levodopa/carbidopa immediate release powder. Rats were administered the different formulations of levodopa/carbidopa (20/5 mg/kg) per os every 12 hours. The pharmacokinetic parameters of levodopa were estimated for the various treatment groups. The percentage content of levodopa and carbidopa in the various formulations was within the acceptance criteria. The AUC0-24 for levodopa/carbidopa multiparticulate matrix (Formulation 3: 484.98 ± 18.70 µg.hr/mL); Formulation 4: 535.60 ± 33.04 µg.hr/mL), and Cmax (Formulation 3: 36.28 ± 1.52 μg/mL; Formulation 4: 34.80 ± 2.19 μg/mL) were higher than Sinemet® CR (AUC0-24 262.84 ± 16.73 µg.hr/mL and Cmax 30.62 ± 3.37 μg/mL). The t1/2 of the new formulation was longer compared to Sinemet® CR.Keywords
This publication has 41 references indexed in Scilit:
- Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systemsMaturitas, 2013
- Design of an Interpolyelectrolyte Gastroretentive Matrix for the Site-Specific Zero-Order Delivery of Levodopa in Parkinson’s DiseaseAAPS PharmSciTech, 2013
- Electrospun biphasic drug release polyvinylpyrrolidone/ethyl cellulose core/sheath nanofibersActa Biomaterialia, 2013
- Chitosan-based drug delivery systemsEuropean Journal of Pharmaceutics and Biopharmaceutics, 2012
- Mucoadhesive buccal patches based on interpolymer complexes of chitosan–pectin for delivery of carvedilolSaudi Pharmaceutical Journal, 2012
- Pharmacokinetic evaluation and modeling of formulated levodopa intranasal delivery systemsEuropean Journal of Pharmaceutical Sciences, 2009
- Chitosan/pectin polyelectrolyte complexes: Selection of suitable preparative conditions for colon-specific delivery of vancomycinEuropean Journal of Pharmaceutical Sciences, 2008
- Biphasic release of indomethacin from HPMC/pectin/calcium matrix tablet: I. Characterization and mechanistic studyEuropean Journal of Pharmaceutics and Biopharmaceutics, 2007
- Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implicationsThe Lancet Neurology, 2006
- Selection of excipients for extended release formulations of glipizide through drug–excipient compatibility testingJournal of Pharmaceutical and Biomedical Analysis, 2005